| Relugolix studied in …STUDIED_INderived10 of 35show all (up to 200) |
|---|
| → studied in | NCT07025369Phase 2 · recruiting Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06111781Phase 2 · recruiting The SUGAR Study; SBRT and Relugolix) for Prostate Cancer · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423211Phase 3 · recruiting Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04513717Phase 3 · active not recruiting Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050084Phase 3 · active not recruiting Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05053152Phase 2 · active not recruiting Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study · 35 trials list this drug (17 active) | — | — | Prostate Adenocarcinoma,Prostate Intraductal Carcinoma,Malignant Prostate Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07455903Phase 2 · recruiting Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05765500Phase 2 · recruiting RecoverPC: Relugolix vs GnRH Agonist in Quality of Life · 35 trials list this drug (17 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06378866Phase 2 · recruiting Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma,Castration-Sensitive Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05467176completed A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX · 35 trials list this drug (17 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |